Phase 1b, open-Label, dose escalation study of quizartinib in combination with induction and consolidation chemotherapy in Japanese patients with newly diagnosed acute myeloid leukemia (AML)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Nov 2017
At a glance
- Drugs Quizartinib (Primary) ; Cytarabine; Daunorubicin; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 14 Nov 2017 Planned End Date changed from 30 Jun 2018 to 1 Jun 2018.
- 14 Nov 2017 Planned primary completion date changed from 1 Nov 2017 to 1 May 2018.
- 13 Nov 2017 Planned End Date changed from 31 Dec 2017 to 30 Jun 2018.